Skip to main content
PMC home page
The American Journal of Pathology logoLink to The American Journal of Pathology
. 1994 Feb;144(2):296–302.

Genesis of squamous cell lung carcinoma. Sequential changes of proliferation, DNA ploidy, and p53 expression.

T Hirano 1, B Franzén 1, H Kato 1, Y Ebihara 1, G Auer 1
PMCID: PMC1887133  PMID: 7906095

Abstract

Squamous cell lung carcinomas (SCCs) represent a highly malignant group of tumors, and effective treatment is greatly dependent upon early diagnosis. However, objective diagnosis of atypia is difficult and useful markers need to be defined. In this study, genomic instability, cell proliferation, and cellular accumulation of mutant p53, as reflected by DNA aneuploidy, proliferating cell nuclear antigen, and p53 immunoreactivity, respectively, were evaluated in bronchial squamous metaplasia without atypia (n = 4), bronchial squamous metaplasia with low-grade atypia (n = 12), bronchial squamous metaplasia with high-grade atypia (n = 15), early-stage SCC (n = 15), and advanced-stage SCC (n = 33). Our results suggest that hyperproliferation is an early event followed by DNA aneuploidy, which in turn precedes p53 immunoreactivity in the genesis of SCC. We conclude that routine assessment of proliferating cell nuclear antigen, DNA ploidy, and p53 may be valuable for the early diagnosis of SCC.

Full text

PDF
296

Images in this article

300Figure 2
on p.300

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Auer G., Ono J., Nasiell M., Caspersson T., Kato H., Konaka C., Hayata Y. Reversibility of bronchial cell atypia. Cancer Res. 1982 Oct;42(10):4241–4247. [PubMed] [Google Scholar]
  2. Baker S. J., Fearon E. R., Nigro J. M., Hamilton S. R., Preisinger A. C., Jessup J. M., vanTuinen P., Ledbetter D. H., Barker D. F., Nakamura Y. Chromosome 17 deletions and p53 gene mutations in colorectal carcinomas. Science. 1989 Apr 14;244(4901):217–221. doi: 10.1126/science.2649981. [DOI] [PubMed] [Google Scholar]
  3. Bravo R., Frank R., Blundell P. A., Macdonald-Bravo H. Cyclin/PCNA is the auxiliary protein of DNA polymerase-delta. Nature. 1987 Apr 2;326(6112):515–517. doi: 10.1038/326515a0. [DOI] [PubMed] [Google Scholar]
  4. Celis J. E., Celis A. Cell cycle-dependent variations in the distribution of the nuclear protein cyclin proliferating cell nuclear antigen in cultured cells: subdivision of S phase. Proc Natl Acad Sci U S A. 1985 May;82(10):3262–3266. doi: 10.1073/pnas.82.10.3262. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Erhardt K., Auer G., Fallenius A., Folin A., Forsslund G., Silfverswärd C., Zetterberg A. Prognostic significance of nuclear DNA analysis in histological sections in mammary carcinoma. Am J Clin Oncol. 1986 Apr;9(2):117–125. doi: 10.1097/00000421-198604000-00003. [DOI] [PubMed] [Google Scholar]
  6. Fearon E. R., Vogelstein B. A genetic model for colorectal tumorigenesis. Cell. 1990 Jun 1;61(5):759–767. doi: 10.1016/0092-8674(90)90186-i. [DOI] [PubMed] [Google Scholar]
  7. Gaub J., Auer G., Zetterberg A. Quantitative cytochemical aspects of a combined feulgen-naphthol yellow S staining procedure for the simultaneous determination of nuclear and cytoplasmic proteins and DNA in mammalian cells. Exp Cell Res. 1975 May;92(2):323–332. doi: 10.1016/0014-4827(75)90386-9. [DOI] [PubMed] [Google Scholar]
  8. Hsu I. C., Metcalf R. A., Sun T., Welsh J. A., Wang N. J., Harris C. C. Mutational hotspot in the p53 gene in human hepatocellular carcinomas. Nature. 1991 Apr 4;350(6317):427–428. doi: 10.1038/350427a0. [DOI] [PubMed] [Google Scholar]
  9. Iggo R., Gatter K., Bartek J., Lane D., Harris A. L. Increased expression of mutant forms of p53 oncogene in primary lung cancer. Lancet. 1990 Mar 24;335(8691):675–679. doi: 10.1016/0140-6736(90)90801-b. [DOI] [PubMed] [Google Scholar]
  10. Kato H., Konaka C., Hayata Y., Ono J., Iimura I., Matsushima Y., Tahara M., Lei J., Nasiell M., Auer G. Lung cancer histogenesis following in vivo bronchial injections of 20-methylcholanthrene in dogs. Recent Results Cancer Res. 1982;82:69–86. doi: 10.1007/978-3-642-81768-7_7. [DOI] [PubMed] [Google Scholar]
  11. Klein N., Vignaud J. M., Sadmi M., Plenat F., Borelly J., Duprez A., Martinet Y., Martinet N. Squamous metaplasia expression of proto-oncogenes and P 53 in lung cancer patients. Lab Invest. 1993 Jan;68(1):26–32. [PubMed] [Google Scholar]
  12. Kurki P., Vanderlaan M., Dolbeare F., Gray J., Tan E. M. Expression of proliferating cell nuclear antigen (PCNA)/cyclin during the cell cycle. Exp Cell Res. 1986 Sep;166(1):209–219. doi: 10.1016/0014-4827(86)90520-3. [DOI] [PubMed] [Google Scholar]
  13. Lane D. P. Cancer. p53, guardian of the genome. Nature. 1992 Jul 2;358(6381):15–16. doi: 10.1038/358015a0. [DOI] [PubMed] [Google Scholar]
  14. Lee J. S., Lippman S. M., Hong W. K., Ro J. Y., Kim S. Y., Lotan R., Hittelman W. N. Determination of biomarkers for intermediate end points in chemoprevention trials. Cancer Res. 1992 May 1;52(9 Suppl):2707s–2710s. [PubMed] [Google Scholar]
  15. Levine A. J., Momand J., Finlay C. A. The p53 tumour suppressor gene. Nature. 1991 Jun 6;351(6326):453–456. doi: 10.1038/351453a0. [DOI] [PubMed] [Google Scholar]
  16. Levine A. J. The p53 tumour suppressor gene and product. Cancer Surv. 1992;12:59–79. [PubMed] [Google Scholar]
  17. Loeb L. A. Mutator phenotype may be required for multistage carcinogenesis. Cancer Res. 1991 Jun 15;51(12):3075–3079. [PubMed] [Google Scholar]
  18. Maltzman W., Czyzyk L. UV irradiation stimulates levels of p53 cellular tumor antigen in nontransformed mouse cells. Mol Cell Biol. 1984 Sep;4(9):1689–1694. doi: 10.1128/mcb.4.9.1689. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Mazars R., Spinardi L., BenCheikh M., Simony-Lafontaine J., Jeanteur P., Theillet C. p53 mutations occur in aggressive breast cancer. Cancer Res. 1992 Jul 15;52(14):3918–3923. [PubMed] [Google Scholar]
  20. Mittal K. R., Demopoulos R. I., Goswami S. Proliferating cell nuclear antigen (cyclin) expression in normal and abnormal cervical squamous epithelia. Am J Surg Pathol. 1993 Feb;17(2):117–122. doi: 10.1097/00000478-199302000-00003. [DOI] [PubMed] [Google Scholar]
  21. Nasiell M., Carlens E., Auer G., Hayata Y., Kato H., Konaka C., Roger V., Nasiell K., Enstad I. Pathogenesis of bronchial carcinoma, with special reference to morphogenesis and the influence on the bronchial mucosa of 20-methylcholanthrene and cigarette smoking. Recent Results Cancer Res. 1982;82:53–68. doi: 10.1007/978-3-642-81768-7_6. [DOI] [PubMed] [Google Scholar]
  22. Nuorva K., Soini Y., Kamel D., Autio-Harmainen H., Risteli L., Risteli J., Vähäkangas K., Päkkö P. Concurrent p53 expression in bronchial dysplasias and squamous cell lung carcinomas. Am J Pathol. 1993 Mar;142(3):725–732. [PMC free article] [PubMed] [Google Scholar]
  23. Ono J., Auer G., Caspersson T., Nasiell M., Saito T., Konaka C., Kato H., Hayata Y. Reversibility of 20-methylcholanthrene-induced bronchial cell atypia in dogs. Cancer. 1984 Sep 15;54(6):1030–1037. doi: 10.1002/1097-0142(19840915)54:6<1030::aid-cncr2820540617>3.0.co;2-9. [DOI] [PubMed] [Google Scholar]
  24. Pendleton N., Dixon G. R., Burnett H. E., Occleston N. L., Myskow M. W., Green J. A. Expression of proliferating cell nuclear antigen (PCNA) in dysplasia of the bronchial epithelium. J Pathol. 1993 Jun;170(2):169–172. doi: 10.1002/path.1711700212. [DOI] [PubMed] [Google Scholar]
  25. Rodrigues N. R., Rowan A., Smith M. E., Kerr I. B., Bodmer W. F., Gannon J. V., Lane D. P. p53 mutations in colorectal cancer. Proc Natl Acad Sci U S A. 1990 Oct;87(19):7555–7559. doi: 10.1073/pnas.87.19.7555. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Shohat O., Greenberg M., Reisman D., Oren M., Rotter V. Inhibition of cell growth mediated by plasmids encoding p53 anti-sense. Oncogene. 1987;1(3):277–283. [PubMed] [Google Scholar]
  27. Sidransky D., Von Eschenbach A., Tsai Y. C., Jones P., Summerhayes I., Marshall F., Paul M., Green P., Hamilton S. R., Frost P. Identification of p53 gene mutations in bladder cancers and urine samples. Science. 1991 May 3;252(5006):706–709. doi: 10.1126/science.2024123. [DOI] [PubMed] [Google Scholar]
  28. Sozzi G., Miozzo M., Donghi R., Pilotti S., Cariani C. T., Pastorino U., Della Porta G., Pierotti M. A. Deletions of 17p and p53 mutations in preneoplastic lesions of the lung. Cancer Res. 1992 Nov 1;52(21):6079–6082. [PubMed] [Google Scholar]
  29. Sundaresan V., Ganly P., Hasleton P., Rudd R., Sinha G., Bleehen N. M., Rabbitts P. p53 and chromosome 3 abnormalities, characteristic of malignant lung tumours, are detectable in preinvasive lesions of the bronchus. Oncogene. 1992 Oct;7(10):1989–1997. [PubMed] [Google Scholar]
  30. Takahashi T., Nau M. M., Chiba I., Birrer M. J., Rosenberg R. K., Vinocour M., Levitt M., Pass H., Gazdar A. F., Minna J. D. p53: a frequent target for genetic abnormalities in lung cancer. Science. 1989 Oct 27;246(4929):491–494. doi: 10.1126/science.2554494. [DOI] [PubMed] [Google Scholar]
  31. Vähäkangas K. H., Samet J. M., Metcalf R. A., Welsh J. A., Bennett W. P., Lane D. P., Harris C. C. Mutations of p53 and ras genes in radon-associated lung cancer from uranium miners. Lancet. 1992 Mar 7;339(8793):576–580. doi: 10.1016/0140-6736(92)90866-2. [DOI] [PubMed] [Google Scholar]

Articles from The American Journal of Pathology are provided here courtesy of American Society for Investigative Pathology

RESOURCES